506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma

You may be eligible if

• Histologically confirmed relapsed or refractory cutaneous T-cell lymphoma
• * Large cell transformation of cutaneous T-cell lymphoma allowed
• No active CNS disease
• Performance status - Zubrod 0-2
• Absolute neutrophil count at least 1,000/mm\^3\*
• Platelet count at least 100,000/mm\^3\*
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGPT no greater than 2.5 times ULN
• Creatinine clearance greater than 50 mL/min
• No history of symptomatic cardiac dysfunction
• No history of pericardial effusion
• HIV negative
• No grade 2 or greater sensory or motor neuropathy
• No history of seizures
• No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin of carcinoma in situ of the cervix
• No medical, psychiatric, or social condition that would preclude study
• No other concurrent serious illness or active infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior stem cell or bone marrow transplantation (BMT)
• No more than 1 prior immunotherapy regimen
• No more than 3 prior systemic regimens with denileukin diftitox
• At least 3 weeks since prior biologic therapy
• No concurrent BMT
• No prior 506U78
• No more than 3 prior systemic chemotherapy regimens comprising any of the following:
• * Oral methotrexate
• * Topical mechlorethamine
• At least 3 weeks since prior chemotherapy
• No other concurrent chemotherapy
• At least 3 weeks since prior anticancer endocrine therapy
• No concurrent topical or systemic steroids
• At least 3 weeks since prior radiotherapy
• No more than 3 prior systemic regimens comprising any of the following:
• * Total skin electron beam therapy
• * Spot radiotherapy
• No more than 3 prior systemic regimens comprising any of the following:
• * Oral retinoids
• * Ultraviolet therapy (PUVA)
• At least 3 weeks since prior anticancer therapy